Related Experiment Videos
Diagnosis and management of lipoprotein abnormalities
Marcelo C Batiste1, Ernst J Schaefer
1Lipid and Heart Disease Prevention Clinic, Tufts-New England Medical Center, Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA.
Insights
Abnormal lipid profiles, including high LDL cholesterol and low HDL cholesterol, increase coronary heart disease risk. Treatment focuses on diet, statins, and specific therapies for severe hypertriglyceridemia and elevated lipoprotein (a).
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Lipidology
Background:
- Abnormal lipid and lipoprotein cholesterol values are defined by specific thresholds for LDL-C, HDL-C, triglycerides (TG), and lipoprotein (a) (Lp(a)).
- These abnormal values are significant risk factors for coronary heart disease (CHD).
- Current guidelines emphasize optimizing LDL-C, particularly in high-risk individuals.
Purpose of the Study:
- To outline current recommendations for managing abnormal lipid profiles.
- To detail treatment strategies for various dyslipidemias, including hypertriglyceridemia and elevated Lp(a).
- To highlight the role of diet and pharmacologic interventions in reducing CHD risk.
Main Methods:
- Review of National Cholesterol Education Program Adult Treatment Panel III guidelines.
- Discussion of dietary interventions: saturated fat and cholesterol restriction.
- Overview of pharmacologic treatments: HMG-CoA reductase inhibitors, fibrates, and niacin.
Main Results:
- Dietary modifications and HMG-CoA reductase inhibitors are primary treatments for lowering LDL-C and reducing CHD risk.
- Fat restriction, glucose control, and fibrates are indicated for severe hypertriglyceridemia to prevent pancreatitis.
- Niacin is effective for lowering Lp(a) and increasing HDL-C.
Conclusions:
- Management of abnormal lipid profiles involves a multi-faceted approach combining lifestyle changes and targeted pharmacotherapy.
- Treatment strategies are tailored to specific lipid abnormalities and patient risk factors.
- Effective lipid management is crucial for substantial reduction in coronary heart disease risk.
Abstract:
Abnormal lipid and lipoprotein cholesterol values have been defined as a low-density lipoprotein (LDL) cholesterol (C) value of 160 mg/dL (4.1 mmol/L) or greater, a high-density lipoprotein (HDL) C value less than 40 mg/dL (1.0 mmol/L), triglycerides (TG) 150 mg/dL (1.7 mmol/L) or greater, and a lipoprotein (a) (Lp(a)) of 30 mg/dl or greater. Such values all increase coronary heart disease (CHD) risk. The National Cholesterol Education Program Adult Treatment Panel III guidelines continue to focus on optimizing LDL-C values (established as < 100 mg/dL or 2.6 mmol/L), especially in those with established CHD, diabetes, or a 10-year CHD risk over 20%. Dietary saturated fat (< 7% of calories) and cholesterol (< 200 mg/day) restriction, and the use of 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are the mainstays of treatment in this regard. Such treatment substantially reduces CHD risk. Severe hypertriglyceridemia (> 1000 mg/dL or 11.0 mmol/L) is associated with pancreatitis, and fat restriction, control of glucose, and fibrate therapy are indicated in such patients. Niacin is currently the most effective agent for lowering Lp(a) and raising HDL-C. Current recommendations for treatment by diet and drugs are outlined.